TITLE

ACE Inhibitors/ARBs for Aortic Stenosis?

AUTHOR(S)
Boyle, Andrew J.
PUB. DATE
October 2011
SOURCE
Internal Medicine Alert;10/29/2011, Vol. 33 Issue 20, p156
SOURCE TYPE
Periodical
DOC. TYPE
Abstract
ABSTRACT
An abstract related to a research conducted on examining whether the use of angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) is beneficial in patients with aortic stenosis (AS), is presented.
ACCESSION #
69591491

 

Related Articles

  • Are angiotensin converting enzyme inhibitors beneficial in patients with aortic stenosis? Shavelle, D. M. // Heart;Oct2005, Vol. 91 Issue 10, p1257 

    Questions as to whether angiotensin converting enzyme inhibitors beneficial in patients with aortic stenosis. Information on the initial studies of angiotensin converting enzyme inhibitors and aortic stenosis; Similarities between aortic stenosis and atherosclerosis; Limitations to the study of...

  • Images In Cardiology: Unicuspid aortic valve Krishnamoorthy, K M // Heart;Feb2001, Vol. 85 Issue 2, p217 

    The article offers information on a unicuspid unicommissural valve revealed through transoesophageal echocardiography in a 16-year-old boy with aortic stenosis.

  • CHOICE: High device success rate with Sapien XT transcatheter valve.  // Cardiology Today;May2014, Vol. 17 Issue 5, p20 

    The article discusses research being done on the use of the Sapien XT transcatheter valve in patients with high-risk aortic stenosis, which references a study by Mohamed Abdel-Wahab et al. presented at the 2014 American College of Cardiology (ACC) Scientific Sessions.

  • Rapid development of severe aortic stenosis from calcification of congenital bicuspid valve. Brooks, Nicholas // British Medical Journal;8/9/1980, Vol. 281 Issue 6237, p424 

    Investigates the rapid development of severe aortic stenosis from calcification of congenital bicuspid valve in London, England. Reference on the cases of a woman and man with the signs of aortic stenosis; Cause of rapid development of severe obstruction; Diagnosis of aortic stenosis; Need of...

  • . . . and has its work cut out. Messerli, Franz H.; Makani, Harikrishna; Bangalore, Sripal // BMJ: British Medical Journal;3/23/2013, Vol. 346 Issue 7900, p23 

    The article discusses medicine campaign needed to tackle two issues, public understanding of the value of screening tests and the private sector's role.

  • Data support broad use of ACE inhibition for CHF, LV dysfunction.  // Geriatrics;Aug94, Vol. 49 Issue 8, p54 

    Presents the summary of an article entitled `Angiotensin-Converting Enzyme Inhibitors in Heart Failure: New Strategies Justified by Recent Clinical Trials' conducted by J.B. Young published in the 1994 issue of the `International Journal of Cardiology'.

  • Patient can't swallow? Go ahead and mix this ACE inhibitor. Hurley, Mary Lou // RN;Sep95, Vol. 58 Issue 9, p71 

    Reports that the US Food and Drug Administration (FDA) has allowed the manufacturer of the angiotensin converting enzyme (ACE) inhibitor, ramipril (Altace), to include mixing instructions in the product literature of the drug. Drinks with which the drug can be mixed.

  • ACE side effects.  // Mayo Clinic Health Letter;Jan2013, Vol. 31 Issue 1, p7 

    The author discusses that patients with kidney dysfunction can face several adverse effects with the administration of angiotensin converting enzyme (ACE) inhibitor, which include fatigue, rash, and headaches.

  • Scott-Levin--latest reports.  // Drug Topics;7/24/95, Vol. 139 Issue 14, p23 

    Presents the May 1995 audit of leading angiotensin converting enzyme (ACE) inhibitors in oral solids form by Scott-Levin Associates. Information gathered from 75% of the retail market; Possible discrepancies between April and May Rx activity data.

  • ENALAPRILAT PREVENTS VASCULAR FUNCTION IN DAUNORUBICIN-INDUCED CARDIOTOXICITY. Kroslakova, Miroslava; Bajuszova, Zuzana; Kmecova, Jana; Krenek, Peter; Ochodnicky, Peter; Klimas, Jan // Biomedical Papers of the Medical Faculty of Palacky University i;2007, Vol. 151, p42 

    An abstract of the medical research "ENALAPRILAT PREVENTS VASCULAR FUNCTION IN DAUNORUBICIN-INDUCED CARDIOTOXICITY," by Miroslava Kroslakova, Zuzana Bajuszova, Jana Kmecova, Peter Krenek, Peter Ochodnicky and Jan Klimas is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics